LYELL IMMUNOPHARMA INC (LYEL)
US55083R1041 - Common Stock
ChartMill assigns a Buy % Consensus number of 47% to LYEL. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 1.02. This target is 58.14% above the current price.
LYEL was analyzed by 9 analysts. The buy percentage consensus is at 47. So analysts seem to be rather neutral about LYEL.
In the previous month the buy percentage consensus was at a similar level.
LYEL was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-11-12 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-10-30 | B of A Securities | Downgrade | Buy -> Underperform |
| 2024-10-28 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-08-19 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-06-27 | B of A Securities | Maintains | Buy -> Buy |
| 2024-06-27 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-05-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-28 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2023-05-05 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-02 | HC Wainwright & Co. | Maintains | Buy |
| 2023-01-24 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-11-14 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2022-11-11 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2022-10-17 | HC Wainwright & Co. | Initiate | Buy |
| 2022-05-24 | Goldman Sachs | Maintains | Buy |
| 2022-01-06 | Morgan Stanley | Maintains | Overweight |
| 2021-07-12 | JP Morgan | Initiate | Overweight |
| 2021-07-12 | Goldman Sachs | Initiate | Buy |
| 2021-07-12 | B of A Securities | Initiate | Buy |
| 2021-07-12 | Morgan Stanley | Initiate | Overweight |